Skip to main content

United States News All stories

Every story in this section, newest first — page 365 of 373.

Grafa
Transport and logistics

Norwegian Cruise Line shares rise on positive Carnival outlook

Shares of Norwegian Cruise Line (NYSE:NCLH) rose by 5.9% in the morning session after its competitor, Carnival, announced strong future guidance and reinstated its dividend, fueling investor optimism across the cruise industry.

Carnival projected an adjusted net income of $3.5 billion for fiscal 2026, surpassing analysts’ expectations, and declared the return of its quarterly dividend.

Read more: Norwegian Cruise Line shares rise on positive Carnival outlook
Grafa
Technology

U.S. antitrust agencies clear Nvidia’s $5B investment in Intel

The U.S. Federal Trade Commission (FTC) has cleared Nvidia’s $5 billion investment in Intel (NASDAQ:INTC), a significant move that could reshape the semiconductor landscape.

The approval comes amid concerns that the deal could alter competition dynamics, particularly impacting rivals such as Taiwan’s TSMC and U.S.-based AMD.

Read more: U.S. antitrust agencies clear Nvidia’s $5B investment in Intel
Grafa
Health

Spero announces GSK resubmission of NDA for tebipenem HBr to treat cUTI

Spero Therapeutics (NASDAQ:SPRO) announced today that its development partner, GSK (NYSE:GSK), has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tebipenem HBr, a treatment for complicated urinary tract infections (cUTI), including pyelonephritis.

Read more: Spero announces GSK resubmission of NDA for tebipenem HBr to treat cUTI
Grafa
Health

Psyence BioMed receives ethics approval for psilocybin trial in cancer patients

Psyence BioMed (NASDAQ:PBM) announced that it has received approval from the Bellberry Human Research Ethics Committee to use its psilocybin product, NPX5, in its ongoing Phase IIb clinical trial for adjustment disorder in cancer patients.

Read more: Psyence BioMed receives ethics approval for psilocybin trial in cancer patients
Grafa
Health

Altimmune's pemvidutide achieves key milestones in IMPACT Phase 2b trial for MASH

Altimmune (NASDAQ:ALT), a clinical-stage biopharmaceutical company focused on therapies for liver diseases, today announced encouraging topline results from its IMPACT Phase 2b trial of pemvidutide, a dual glucagon/GLP-1 receptor agonist, in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Read more: Altimmune's pemvidutide achieves key milestones in IMPACT Phase 2b trial for MASH